Showing 1411-1420 of 2526 results for "".
- MeiraGTx’s Unveils Gene Therapy Manufacturing Facility in Shannon, Irelandhttps://modernod.com/news/meiragtxs-unveils-gene-therapy-manufacturing-facility-in-shannon-ireland/2481098/MeiraGTx Holdings will formally unveil its GMP manufacturing facility in Shannon, Ireland, with the Head of Irish Government, Micheál Martin, in attendance. The facility, online since earlier this year and stretching over 150,000 square feet, is the first commercial-scale ge
- BVI Announces Certification for its IOL Portfolio Under the European Medical Device Regulationhttps://modernod.com/news/bvi-announces-certification-for-its-iol-portfolio-under-the-european-medical-device-regulation/2481094/BVI announced certification for its IOL portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medica
- Envision University Sets Agenda for Virtual Fall Conference 2022https://modernod.com/news/envision-university-sets-agenda-for-virtual-fall-conference-2022/2481075/Organizers of the Envision Conference through Envision University have set the agenda for Envision Virtual Fall Conference with sessions and opportunities for professionals in the vision rehabilitation field. The conference will be October 7-8, 2022, via livestream webinar. Envision Conference is
- Harrow Health Announces Launch of Iopidine 1% and Maxitrol in the United Stateshttps://modernod.com/news/harrow-health-announces-launch-of-iopidine-1-and-maxitrol-in-the-united-states/2480929/Harrow Health announced the completion of the transfer to Harrow of the new drug applications (NDAs) of recently acquired, FDA-approved ophthalmic medicines, Iopidine 1%, Maxitrol 3.5mg/10,000 units/0.1%, and Moxeza 0.5%. Harrow also announced that Iopidine 1% and Maxitrol are
- United Kingdom First to Grant License for Teva’s Ophthalmology Biosimilar Ongavia (Ranibizumab)https://modernod.com/news/united-kingdom-first-to-grant-license-for-tevas-ophthalmology-biosimilar-ongavia-ranibizumab/2480870/Teva Pharmaceutical announced that the UK Medicines & Healthcare Regulatory Agency (MHRA) has granted a licence for Ongavia, a biosimilar to Lucentis (ranibizumab). The United Kingdom is the first country in Europe to authorize commercialization of Ongavia for
- Centricity Vision Announces New Technologies Under Development, Zeptolink and 5.5 mm Capsulotomy; Names Leonard Borrmann to Lead R&Dhttps://modernod.com/news/centricity-vision-announces-new-technologies-under-development-zeptolink-and-55-mm-capsulotomy-names-leonard-borrmann-to-lead-rd/2480783/Centricity Vision announced two product innovations under development, the Zeptolink platform and Zepto 5.5 mm capsulotomy technology. The company has also appointed Leonard Borrmann, PharmD, to lead research and development. "The Zepto technology is elevating the precisi
- Envision University Sets Agenda for In-Person May 2022 Conferencehttps://modernod.com/news/envision-university-sets-agenda-for-in-person-may-2022-conference/2480768/Organizers of the Envision Conference through Envision University have set the agenda for Envision Conference East with outstanding sessions and opportunities for professionals in the vision rehabilitation field. The conference will be held on May 19-21, 2022, at the Ohio State University, in col
- Kala Pharmaceuticals Announces Eysuvis Now Covered on UnitedHealthcare Commercial and Cigna Medicarehttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-on-unitedhealthcare-commercial-and-cigna-medicare/2480681/Kala Pharmaceuticals announced that UnitedHealthcare, one of the largest commercial health care plans in the United States covering approximately 13 million people, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies eff
- I-Med Pharma USA Partners With DryEye Rescue to Distribute Its Dry Eye Product Portfolio in the United Stateshttps://modernod.com/news/i-med-pharma-usa-partners-with-dryeye-rescue-to-distribute-its-dry-eye-product-portfolio-in-the-united-states/2480614/With the recent launch of its line of dry eye diagnostics, management, and treatment solutions into the United States, I-MED Pharma USA has partnered with DryEye Rescue of Boca Raton, Florida to distribute and market their dry eye product portfolio. DryEye Rescue will help raise awareness of
- Using Cryo-Electron Tomography, UCI Researchers Reveal Molecular Mechanisms Underlying Mutations Within the Eye that Lead to Blindnesshttps://modernod.com/news/uc-irvine-researchers-reveal-molecular-mechanisms-of-eye-disease-using-cryo-electron-tomography/2480586/For the first time, University of California, Irvine researchers in collaboration with the Max-Planck Institute of Biochemistry, have revealed, at a molecular level, key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrument